Table 7.
Cross-type protection against 6-month persistent infection
| Efficacy (95% CI) | |||
|---|---|---|---|
| Trial: | FutureI/II | PATRICIA | CVT |
| Vacccine: | Gardasil® | Cervarix® | Cervarix® |
| Cohort: | ITT-Naive | TVC-Naive | ATP |
| Mean | 3.6 yrs | 3.3 yrs | 4 yrs |
| Follow-up: | |||
| HPV31 | 46.2 (15.3–66.4) | 77.1 (67.2–84.4) | 64.7 (42.6–78.9) |
| HPV33 | 28.7 (45.1–65.4) | 43.1 (19.3–60.2) | 32.1 (41.1–68.2) |
| HPV35 | 17.8 (77.1–62.5) | 21.8 (102.5–26.2) | 25.0 (40.6–60.6) |
| HPV52 | 18.4 (−20–45.0) | 18.9 (3.2–32.2) | 19.6 (8.1–40.4) |
| HPV58 | 5.5 (54.3–42.2) | 6.2 (44.0–21.6) | 2.8 (48.0–36.2) |
| Non-Vaccine A9 | 21.9 (0.6–38.8) | 27.6 (17.6–36.5) | NR |
| HPV39 | NRa | 20.9 (2.3–39.9) | 30.8 (109.2–17.6) |
| HPV45 | 7.8 (67.0–49.3) | 79.0 (61.3–89.4) | 73.0 (45.3–87.8) |
| HPV59 | 18.7 (22.8–46.4) | 3.9 (61.7–33.1) | 30.3 (130.3–25.6) |
| HPV68 | NR | 8.9 (18.8–30.1) | NR |
| Non-vaccine A7 | 14.8 (19.9–39.6)b | 22.3 (8.4–34.2) | NR |
| HPV51 | NR | 25.5 (12.0–37.0) | 56.1 (114.3–14.2) |
| HPV56 | NR | 1.4 (24.8–22.0) | 25.8 (12.7–51.4) |
| HPV66 | NR | 1.5 (29.3–20.3) | 1.6 (41.0–31.3) |